highlights:

  • Osteopore has signed a three-year distribution agreement with Al-Umnia Medical LLC covering five Middle East countries.
  • The agreement expands Osteopore’s orthopaedic product segment into Saudi Arabia, UAE, Oman, Qatar and Bahrain.
  • Product registration processes will begin across the five targeted markets based on local regulatory requirements.
  • The partnership provides a pathway for Osteopore’s 3D-printed biomimetic implants to access the GCC orthopaedic devices sector.

Osteopore Ltd (ASX: OSX) shares were trading at A$0.0050, up A$0.00050 or 11.11% at 10:13 am on 6 August 2026. The share movement followed the company’s announcement that it has entered into a three-year distribution agreement with Al-Umnia Medical LLC for its orthopaedic products across Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain. The agreement represents an expansion of Osteopore’s commercial activities beyond Southeast Asia into the Middle East medical technology market.

Distribution Agreement Expands Orthopaedic Market Presence

Osteopore has partnered with Al-Umnia Medical LLC, a Dubai-based medical technology distributor, to support the introduction of its orthopaedic bone reconstruction products across five Gulf Cooperation Council (GCC) countries.

The agreement has an initial term of three years, with an option for a further one-year extension. The arrangement focuses on the distribution of Osteopore’s orthopaedic bone reconstruction product segment, with commercial activities subject to product registration requirements in each market.

Al-Umnia was established in Dubai in 2009 and has developed a multi-department organisation focused on partnerships with international medical technology companies. The company operates across the GCC region and provides clinical education, training, and support services associated with medical product distribution.

Middle East Healthcare Opportunity Supports Expansion Strategy

The Middle East represents a targeted growth region for orthopaedic and regenerative medicine technologies. According to market data referenced by Osteopore, the GCC orthopaedic devices market was valued at approximately US$897.5 million in 2025 and is forecast to reach US$1.55 billion by 2034, representing a compound annual growth rate of 6.04%.

Within the GCC region, the United Arab Emirates represents the largest single market, accounting for approximately 31.5% of the market. Synthetic bone substitutes represent a distinct segment within the broader orthopaedic devices sector.

Osteopore’s expansion into these markets aligns with the company’s focus on commercialising 3D-printed biomimetic and bioresorbable implant technologies designed to support natural bone regeneration.

Product Registration and Market Entry Process

Following the agreement, Osteopore and Al-Umnia will proceed with regulatory product registration across Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain.

Each country has individual regulatory frameworks and approval processes for medical devices. The registration process will determine the pathway for commercial availability of Osteopore’s orthopaedic products in each market.

The distribution agreement includes performance-related conditions, with termination provisions linked to non-performance of agreed sales purchase targets.

Osteopore’s Regenerative Medicine Technology Platform

Osteopore develops medical technology products based on 3D printing and bioresorbable materials. The company’s patented technology creates micro-structured scaffolds designed to support bone regeneration while gradually dissolving over time.

The company’s product portfolio is focused on applications where natural bone healing is required across multiple therapeutic areas. Its technology platform is designed to provide an alternative approach to permanent implant solutions by supporting the regeneration process.

The Middle East expansion adds a new geographic focus for Osteopore’s orthopaedic business as the company continues commercialisation activities in international healthcare markets.

Conclusion

Osteopore’s distribution agreement with Al-Umnia Medical LLC establishes a framework for introducing its orthopaedic bone reconstruction products into five Middle Eastern markets. The partnership combines Osteopore’s regenerative medicine technology with Al-Umnia’s regional distribution capabilities, while the companies progress through product registration and market entry processes.